Order 7 Rule 11 CPC | Mere Designation as Director Does Not Create Civil Liability: Bombay High Court Rejects Suit Against Nominee Directors

"A company is a separate and distinct legal entity. A civil claim against a company does not, in law, ipso facto translate into a cause of action against its directors", In a significant ruling Bombay High Court allowed a series of applications under Order VII Rule 11 of the Civil Procedure Code, 1908, filed by Defendant Nos. 3 to 8 . The Court emphatically held that the plaint failed to disclose any cause of action against the directors who were impleaded solely by virtue of their designation as nominee or non-executive directors.

The core legal issue before the Court was whether a civil suit could be sustained against directors of a corporate entity in the absence of specific pleadings as to their personal role, involvement, benefit, or any statutory or contractual liability. Justice Doctor’s judgment resoundingly answered in the negative, reinforcing the principle that the corporate veil cannot be pierced casually or without pleadings of s     ubstance.

“Sweeping and omnibus allegations using the term ‘the Defendants’ are legally insufficient to make individual directors liable.”

At the heart of the dispute lay allegations by the Plaintiff, Multi Commodity Exchange of India Ltd. (MCX), against Defendant Nos. 1 and 2 — corporate entities allegedly engaged, without proper authority, to advise on the sale of MCX’s stake in MCX-SX. The Plaintiff contended that fees aggregating to approximately ₹19.5 crores had been paid to the said companies in pursuance of that engagement. However, as the Court noted, “the Plaint is completely silent as to any role, involvement, or participation of Defendant Nos. 3 to 8 in the alleged transaction or the alleged wrongdoing.”

The Plaintiff had impleaded six individuals — Defendant Nos. 3 to 8 — described in the cause title merely as “Directors” or “Nominee Directors” of Defendant No. 2. It was admitted by the Plaintiff’s counsel during the hearing that the plaint did not contain any individualized allegations against any of these defendants. Instead, the Plaintiff relied on the expression “the Defendants” throughout the plaint, hoping to draw these directors into the frame of liability without stating how they had personally contributed to the alleged harm.

The Court rejected this approach in no uncertain terms, stating: “Vague and omnibus averments are wholly insufficient to disclose or sustain a cause of action against Defendant Nos. 3 to 8.”

“Pleadings must contain more than labels—allegations of fraud, collusion, or conspiracy must be backed by material particulars.”

Justice Doctor reinforced the procedural discipline demanded by Order VI Rule 4 of the CPC, observing that allegations of fraud or collusion must be specifically pleaded with material particulars. “Such bald and generalized allegations,” the Court said, “do not satisfy statutory standards and cannot sustain the impleadment of directors.”

The Plaintiff attempted to justify the inclusion of the directors by referring to an Affidavit-in-Reply filed in one of the Notices of Motion. However, the Court drew a sharp line on the scope of inquiry under Order VII Rule 11:

“The Plaintiff cannot rely on an affidavit in reply to cure defects in the plaint. It is trite law that a cause of action must be disclosed in the plaint itself, and a plaintiff cannot rely upon material outside the plaint to overcome fundamental defects.”

Further, the judgment highlighted that Defendant No. 5, for instance, had resigned from IL&FS (the institution which nominated him as a director) before the suit was even filed. Yet, no pleading had acknowledged this, nor was there any attempt to state how he continued to be responsible for any alleged wrongdoing. Justice Doctor pointed out that “there is no pleading that the said Defendants personally benefited from the alleged transaction, nor any case pleaded for piercing the corporate veil.”

“Participation in Board decisions does not render a director personally liable for contractual obligations of the company.”

Justice Doctor relied on settled jurisprudence, including the Bombay High Court’s earlier decision in ACG PAM Pharma Technologies Pvt. Ltd. v. Dr. Datsons Laboratory & Ors., as well as the Delhi High Court’s view in Space Enterprises v. Srinivasa Enterprises Ltd., both of which hold that in the absence of contractual privity or statutory violation, directors cannot be sued in their personal capacity for acts of the company.

The Supreme Court’s judgment in Electrosteel Castings Ltd. v. UV Asset Reconstruction Co. Ltd. was also cited with approval, particularly for its reaffirmation that allegations of fraud or conspiracy must meet a high threshold of specificity.

In a crucial legal clarification, Justice Doctor affirmed that the rejection of the plaint need not be total and can be directed against only some defendants. “A plaint may be rejected as against some Defendants while being maintainable against others,” he held, citing the Division Bench ruling in Sheela Ram Vidhani & Anr. v. M/s. S.K. Trading Company & Ors.

“Litigants must not attempt to weaponize vague pleadings to pressure nominee directors into litigation.”

Ultimately, the Court concluded that the Plaintiff’s case — even if taken at its highest — rested solely against Defendant Nos. 1 and 2. “On a plain and meaningful reading of the plaint,” Justice Doctor held, “no cause of action is disclosed against Defendant Nos. 3 to 8.” Accordingly, the Notices of Motion filed by those directors were allowed, and the plaint was rejected against them under Order VII Rule 11 CPC.

The suit will now proceed only against the two corporate defendants. The Plaintiff’s attempt to entangle former nominee and non-executive directors in protracted litigation has been firmly rebuffed.

This judgment is not merely a procedural dismissal — it is a timely reminder to litigants and corporate entities that civil liability of directors must be earned through precise pleading, not presumed through association. The sanctity of corporate structure, the integrity of procedural law, and the rights of individual directors stand reaffirmed.

Date of Decision: 5 February 2026